HUEY-LING CHIANGLiu C.C.TZUNG-JENG HWANG2020-10-232020-10-2320090269-8811https://www.scopus.com/inward/record.uri?eid=2-s2.0-65649123029&doi=10.1177%2f0269881108091255&partnerID=40&md5=6b199f30e7501d394b65e7abb35b30d7https://scholars.lib.ntu.edu.tw/handle/123456789/517972Clozapine is known to be associated with higher risk of metabolic syndrome, including dyslipidaemia, but the mechanisms of such a relationship are still under debate. The case we reported shows a seemingly dose-dependent effect of clozapine on a patientgs lipid profiles with no influence on his blood sugar in a relatively short period of time. A direct effect of clozapine on lipid metabolism, independent of insulin or obesity-related metabolic changes, is suggested. The rapid effect of clozapine on lipid profile allows fine-tuning in dose adjustment while treating refractory schizophrenia complicated with drug-related dyslipidaemia but worrying about psychotic rebound during clozapine discontinuation. ? 2009 British Association for Psychopharmacology.[SDGs]SDG3cholesterol; clozapine; ezetimibe; fenofibrate; fluphenazine; fluphenazine decanoate; glucose; haloperidol; triacylglycerol; trifluoperazine; zotepine; zuclopenthixol; adult; article; case report; cholesterol blood level; clinical feature; delusion; dose response; drug dose reduction; drug dose titration; drug effect; dyslipidemia; hallucination; human; irritability; lipid metabolism; male; priority journal; schizophrenia; symptom; triacylglycerol blood level; Antipsychotic Agents; Clozapine; Dose-Response Relationship, Drug; Dyslipidemias; Humans; Male; Middle Aged; Schizophrenia; Time Factorsjournal article10.1177/0269881108091255185624102-s2.0-65649123029